Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Endocrine 1

Conditions

Ovarian Neoplasms 12Small Cell Lung Carcinoma 8Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Neoplasms 4Neuroblastoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Fallopian Tube Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Thrombocytopenia 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1SCLC, Extensive Stage 1Recurrence 1Radiation Injuries 1Primary Myelofibrosis 1Polycythemia Vera 1Peritoneal Neoplasms 1Myoepithelioma 1Myeloproliferative Disorders 1Multiple Myeloma 1Liposarcoma, Myxoid 1

Interventions

atezolizumab 3Etoposide 2Cisplatin 2veliparib 1tivozanib 1surufatinib 1repotrectinib 1pralsetinib 1pembrolizumab 1durvalumab 1berzosertib 1avelumab 1Topotecan 1Podophyllotoxin 1Platinum 1Paclitaxel 1Nivolumab 1Ipilimumab 1Everolimus 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Neuroendocrine × Topotecan × Clear all
NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
62 enrolled 29 charts
EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡